Skip directly to site content
Kidney Disease Surveillance System
Home

Quality of Care

Quality of care includes proper treatment, including lifestyle changes and appropriate medication use. This section presents current albuminuria testing rates among Veterans, medication use for indicated drugs (angiotensin-converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter-2 [SGLT2] inhibitors [among kidney patients with diabetes]), and the avoidance of medications that are toxic to kidneys, including nonsteroidal anti-inflammatory drugs (NSAIDS). These metrics were examined among patients from the Veteran’s Health Administration, study participants (weighting to the US population) from the National Health and Nutrition Examination Survey (NHANES), and insured individuals from the Optum® Clinformatics® database. Additional quality of care measures will be included in subsequent Kidney Disease Surveillance System updates.



eGFR Formula Disclaimer
At the time of the last data update in summer 2022, the race-free eGFR formula was newly recommended and impact on health outcomes is underway. To avoid inconsistent results caused by different formulae, stakeholders continued using the eGFR formula with race during this transition. Since then, comparisons have been made. The estimates for the current website launch are still based on analyses using the eGFR formula with race, however plan is to use race-free eGFR formula for the next data update and upcoming website launch in fall 2023.